Navigation Links
Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
Date:8/27/2012

FREDERICK, Md., Aug. 27, 2012 /PRNewswire/ -- Vaccinogen, Inc. today announced Dr. Michael G. Hanna, Jr., Vaccinogen CEO and co-founder, has served as guest-editor and contributor for the Human Vaccines & Immunotherapeutics Special Focus on cancer vaccines and immunotherapeutics, one of the most comprehensive peer-reviewed discussions published on the field. The Special Focus highlights nearly two decades of research and clinical development programs and, for the first time, identifies tumor heterogeneity among the factors in the success or failure of cancer immunotherapies. The Special Focus also includes direct commentary on the technology platforms for products, clinical trial design issues, and manufacturing hurdles that factor into cancer vaccine development. Dr. Hanna contributed to an introductory overview of the cancer vaccine field, authored a paper on Vaccinogen's lead product OncoVAX®, and provided the summary titled "Cancer vaccines: Are we there yet?"

"There is a new paradigm in patient-specific immunotherapy using cancer vaccines. For decades, researchers developed cancer vaccines using off the shelf presumptive antigen(s) based on a false premise that cancer cells are alike, or homogeneous," said Dr. Hanna. "The vast amount of second generation DNA sequencing data generated over the past few years has clearly demonstrated that tumors are not homogenous. Instead there is heterogeneity in and among tumors of the same classification and pathological stage. These facts indicate that the best immunotherapeutic benefits will be achieved using patient specific therapies.  Vaccinogen's Phase III cancer vaccine for Stage II colon cancer, called OncoVAX, uses this validated approach with the patient's own live tumor cells as the source of the vaccine."

Ronald Ellis, Ph.D, Editor-in-Chief of Human Vaccines & Immunotherapeutics, said, "One of the central themes attributing to the success and failure of cancer vaccines is the heterogeneity of cancer. This principle simply indicates that cancer cells are genetically unique. This means that single-marker therapies that do not account for the diversity of cancer cells might not be successful, or may turn out to have the limited efficacy exhibited by previous monotherapies."

The Special Focus appearing in the August 2012 issue includes an introduction, five original papers, and a guest editorial. The Special Focus can be accessed online at http://www.landesbioscience.com/journals/vaccines/toc/volume/8/issue/8/.

About OncoVAX

OncoVAX® is a patient specific cancer vaccine that unleashes the body's own immune system to fight cancer cells that it otherwise would not have recognized. Currently in Phase III development, OncoVAX is designed to use a patient's own cancer cells to block the return of colon cancer following surgery. OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following gold-standard surgical tumor resection for Stage II colon cancer.  Within 35 days following surgery, patients are vaccinated with OncoVAX to prevent disease recurrence, which is incurable and occurs in as much as 35% of the patients.  Patients are given three vaccinations once per week for three weeks, followed by a booster vaccination after six months. A previously completed Phase III trial published in Lancet showed that OncoVAX cut the risk of recurrence by 61% in patients with Stage II colon cancer.

About Vaccinogen

Vaccinogen, Inc. is a cancer vaccine company developing OncoVAX® as a treatment to prevent the recurrence of colon cancer and potentially other solid tumors. Vaccinogen has developed proprietary technology to use the patient's own live tumor cells as the source of the vaccine. OncoVAX has completed five dose and regimen finding clinical studies, including one Phase III trial with the optimum dose and regimen and will begin a pivotal phase III trial under an FDA Special Protocol Acceptance (SPA) classification, by the end of 2012. More information is available at www.vaccinogeninc.com.


'/>"/>
SOURCE Vaccinogen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Selfhelp Community Services and FEGS Health & Human Services Launch New Care Management Company: SinglePoint Care Network to Coordinate Care for Seniors & Others With Chronic Medical Conditions in Managed Long Term Care Market
2. Human Circuit Recognized as an Industry Leader in Commercial Integrator Magazines Business Series as a Top 5 Healthcare Market Media Integrator for 2012
3. Fetal Surveillance Company, PeriGen, Inc., to Collaborate with National Institute of Child Health and Human Development to Research Fetal Heart Rate Patterns During Labor
4. CeeTox and Cellular Dynamics Collaborate to Offer Predictive In Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells
5. NIH Director Francis S. Collins, M.D., Ph.D. Selected as 2012 Pro Bono Humanum Honoree by Prix Galien USA
6. Man Without Human Heart Hikes More Than 400 Miles
7. Robai Offers Cyton Gamma Humanoid Robot Arm
8. Hologic Human Papillomavirus (HPV) High-Risk Test Approved for Use in The Netherlands Population Cervical Screening Programme
9. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
10. The Healing Power of Human Milk
11. China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 17, 2017 - First major agreements signed ... market expected to grow by a CAGR of approximately 6-9% ... holding company which operates globally across a number of sectors, announces ... of notable successes and is well-positioned for further expansion within the ... ...
(Date:1/16/2017)... Research and Markets has announced the addition of the ... ... myeloma drugs market to grow at a CAGR of 9.19% during ... scenario and the growth prospects of the global multiple myeloma drugs ... the revenue generated from the sales of branded and generic drugs ...
(Date:1/16/2017)... -- An aneurysm develops due to the weakening of blood vessel ... occur in any artery, it happens most often in the ... legs. Most aortic aneurysms occur in the section of the ... abdominal aortic aneurysms, sometimes in the chest referred as thoracic ... abdomen is about 2 cm but in the case of ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... California Southern University has named Dr. Steven ... Board of Trustees and as a core faculty member, teaching master’s and doctoral courses ... of psychology at Pepperdine University, where he earned his Doctor of Psychology degree in ...
(Date:1/16/2017)... Utah (PRWEB) , ... January 16, 2017 , ... With ... officially opened on January 8 for use by sports teams and the general public. ... indoor volleyball courts that can also be converted into basketball or pickleball courts. The ...
(Date:1/16/2017)... Smithtown, New York (PRWEB) , ... January 16, ... ... group, SightMD today announced the addition of Victor Giamos, MD to ... Officer of SightMD and Managing Partner at North Shore Eye Care, a division ...
(Date:1/16/2017)... GA (PRWEB) , ... January 16, 2017 , ... ... to announce their recent partnership with an innovator in the wheelchair accessibility industry, ... to motivate their dealer salespeople to sell wheelchair accessible vehicles. With this new ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Aesthetic Surgery Journal , the official journal of The American Society for Aesthetic ... retraction surgery. The procedure is designed to correct drooping, retracted lower eyelids, which ...
Breaking Medicine News(10 mins):